fortune.com Open in urlscan Pro
18.173.132.55  Public Scan

Form analysis
1 forms found in the DOM

GET https://fortune.com/advanced-search

<form class="queryly-form i-amphtml-form" action="https://fortune.com/advanced-search" target="_top" method="get" novalidate="">
  <input class="queryly-input" name="query" value="" placeholder="Search Fortune...">
  <input class="queryly-submit" type="submit" value="Search">
</form>

Text Content

Dismiss Close
Fortune
Cookies and Related Technologies on This Site
Please choose whether this site may use cookies or related technologies such as
web beacons, pixel tags, and Flash objects (“Cookies”) as described below. You
can learn more about how this site uses cookies and related technologies by
reading our privacy policy linked below.
Accept Reject
Privacy Policy

Ad


Fortune Fortune
search
Subscribe Now
 * Rankings
 * Magazine
 * Newsletters
 * Podcasts
 * Video On Demand
 * Fortune Live Media
 * CEO Initiative
 * Fortune Connect
 * Fortune Education
 * Fortune Well
 * Fortune Crypto
 * Fortune Recommends


Health obesity


MILLIONS OF OLDER AMERICANS CAN’T GET WEIGHT LOSS DRUGS LIKE WEGOVY BECAUSE
MEDICARE WON’T PAY FOR THEM


DRUGMAKERS AND A WIDE-RANGING AND GROWING BIPARTISAN COALITION OF LAWMAKERS ARE
GEARING UP TO PUSH FOR A CHANGE NEXT YEAR.

BY
Amanda Seitz
 AND 
The Associated Press
December 28, 2023 1:51 PM EST

Medicare doesn't usually cover weight loss drugs. Jaap Arriens/NurPhoto via
Getty Images

New obesity drugs are showing promising results in helping some people shed
pounds but the injections will remain out of reach for millions of older
Americans because Medicare is forbidden to cover such medications.

Subscribe to unlock this article and get full access to Fortune.com

Try for $1

Already a member? Login

New obesity drugs are showing promising results in helping some people shed
pounds but the injections will remain out of reach for millions of older
Americans because Medicare is forbidden to cover such medications.



Drugmakers and a wide-ranging and growing bipartisan coalition of lawmakers are
gearing up to push for that to change next year.



As obesity rates rise among older adults, some lawmakers say the United States
cannot afford to keep a decades-old law that prohibits Medicare from paying for
new weight loss drugs, including Wegovy and Zepbound. But research shows the
initial price tag of covering those drugs is so steep it could drain
Medicare’s already shaky bank account.

A look at the debate around if — and how — Medicare should cover obesity drugs:




WHAT OBESITY DRUGS ARE ON THE MARKET AND HOW DO THEY WORK?

The Food and Drug Administration has in recent years approved a new class of
weekly injectables, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, to treat
obesity.



People can lose as much as 15% to 25% of their body weight on the drugs, which
imitate the hormones that regulate appetites by communicating fullness between
the gut and brain when people eat.

The cost of the drugs, beloved by celebrities, has largely limited them to the
wealthy, A monthly supply of Wegovy rings up at $1,300 and Zepbound will put you
out $1,000. Shortages for the drugs have also limited the supplies. Private
insurers often do not cover the medications or place strict restrictions on who
can access them.

Last month, a large, international study found a 20% reduced risk of serious
heart problems such as heart attacks in patients who took Wegovy.




WHY DOESN’T MEDICARE COVER THE DRUGS?

Long before Oprah Winfrey and TikTok influencers alike gushed about the benefits
of these weight loss drugs, Congress made a rule: Medicare Part D, the health
insurance plan for older Americans to get prescriptions, could not cover
medications used to help gain or lose weight. Medicare will cover obesity
screening and behavioral treatment if a person has body mass index over 30.
People with BMIs over 30 are considered obese.

The rule was tacked onto legislation passed by Congress in 2003 that overhauled
Medicare’s prescription drug benefits.

Lawmakers balked at paying high costs for drugs to treat a condition that was
historically regarded as cosmetic. Safety problems in the 1990s with the
anti-obesity treatment known as fen-phen, which had to be withdrawn from the
market, were also fresh in their minds.



Medicaid, the state and federal partnership program for low-income people, does
cover the drugs in some areas, but access is fragmented.


THE CONVERSATION IS SHIFTING

New studies are showing the drugs do more than help patients slim down.

Rep. Brad Wenstrup, R-Ohio, introduced legislation with Rep. Raul Ruiz,
D-Calif., this year that would allow Medicare to cover the now-forbidden
anti-obesity drugs, therapy, nutritionists and dieticians.



“For years there was a stigma against these people, then there was a stigma
about talking about obesity,” Wenstrup said in an interview with The Associated
Press. “Now we’re in a place where we’re saying this is a health problem we need
to deal with this.”

He believes the intervention could alleviate all sorts of ailments associated
with obesity that cost the system money.

“The problem is so prevalent,” Wenstrup said. “People are starting to realize
you have to take into consideration the savings that comes with better health.”



Last year, about 40% of the nearly 66 million people enrolled in Medicare had
obesity. That roughly mirrors the larger U.S. population, where 42% of adults
struggle with obesity, according to the Centers for Disease Control and
Prevention.

Notably, Medicare does cover certain surgical procedures to treat medical
complications of obesity in people with a body mass index of 35 and at least one
related condition. Congress approved the exception in 2006, noted Mark
McClellan, a former head of the Centers for Medicare and Medicaid Services and
the FDA.

The 17-year-old law may provide a blueprint for expanding coverage of the new
drugs, which mirror the results of bariatric surgery in some cases, McClellan
said. Evidence showed that the surgery reduced the risks of death and serious
illness from conditions related to obesity.



“And that’s been the basis for coverage all this time,” McClellan said.


COST IS NOW THE ISSUE

Still, the upfront price tag for lifting the rule remains a challenge.

Some research shows offering weight loss drugs would assure Medicare’s impending
bankruptcy. A Vanderbilt University analysis this year put an annual price of
about $26 billion on anti-obesity drugs for Medicare if just 10% of the system’s
enrollees were prescribed the medication.



Other research, however, shows it could also save the government billions, even
trillions over many years, because it would reduce some of the chronic
conditions and problems that stem from obesity.

An analysis this year from the University of Southern California’s Schaeffer
Center estimated the government could save as much as $245 billion in a decade,
with the majority of savings coming from reducing hospitalizations and other
care.

“What we did is we looked at the long-term health consequences of treating
obesity in the Medicare population,” said the study’s co-author, Darius
Lakdawalla, the director of research at the center. The Schaeffer Center
receives funding from pharmaceutical companies, including Eli Lilly.



Lakdawalla said it’s nearly impossible to put a cost on covering the drugs
because no one knows how many people will end up taking them or what the drugs
will be priced at.

The Congressional Budget Office, which is tasked with pricing out legislative
proposals, acknowledged this difficulty in an October blog post, with the
director calling for more research on the topic.

Overall, the agency “expects that the drug’s net cost to the Medicare program
would be significant over the next 10 years.”



The cost of the legislation is the biggest hang up in getting support, Ruiz
said.

“When we talk about the initial cost, I often have to educate the members that
the CBO does not take into account cost savings in their cost benefit analysis,”
Ruiz told the AP. “Taking that number in isolation, one does not get the full
picture of the full economies of reducing obesity and all of its comorbidities
in our patients.”


WHO WANTS MEDICARE TO COVER THE DRUGS?

Doctors say weight loss drugs are only a part of the most effective strategies
to treat a patient with obesity.



When Dr. Andrew Kraftson develops a plan with his patients at the University of
Michigan’s Weight Navigator program, it involves a “perfect marriage” of
behavioral intervention, health and diet education, and possibly anti-obesity
medication.

But with Medicare patients, he is limited in what he can prescribe.

“A blanket prohibition for use of anti-obesity medication is an antiquated way
of thinking and does not recognize obesity as a disease and is perpetuating
health disparities,” Kraftson said. “I’m not so ignorant to think that Medicare
should just start covering expensive treatments for everyone. But there is
something between all or nothing.”



Lawmakers have introduced some variation of legislation that would permit
Medicare coverage of weight loss drugs over the last decade. But this year’s
bill has garnered interest from more than 60 lawmakers, from self-proclaimed
budget hawk Rep. David Schweikert, R-Ariz., to progressive Rep. Judy Chu,
D-Calif.

Passage is a top priority for two lawmakers, Wenstrup and Sen. Tom Carper,
D-Del., before they retire next year.

Pharmaceutical companies also are readying for a lobbying blitz next year with
the drugs getting the OK from the FDA to be used for weight loss.



“Americans should have access to the medicines that their doctors believe they
should have,” Stephen Ubl, the president of the lobbying group, Pharmaceutical
Research and Manufacturers of America, said on a call with reporters last week.
“We would call on Medicare to cover these medicines.”

Already, Novo Nordisk has employed eight separate firms and spent nearly $20
million on lobbying the federal government on issues, including the Treat &
Reduce Obesity Act, since 2020, disclosures show. Eli Lilly has spent roughly
$2.4 million lobbying since 2021.

Advocates for groups such as the Obesity Society have been pushing for Medicare
coverage of the medications for years. But the momentum may be shifting, thanks
to the growing evidence that the obesity drugs can prevent strokes, heart
attacks, even death, said Ted Kyle, a policy advisor.

“The conversation has shifted from debating whether obesity treatment is
worthwhile to figuring out how to make the economics work,” he said. “This is
why I now believe the change is inevitable.”





MOST POPULAR IN HEALTH

 * Health
   Have a COVID headache? What you can expect, how to treat it, and when it
   might go away
   January 20, 2024
   BY  Erin Prater

 * --------------------------------------------------------------------------------

 * Health
   Not brushing or flossing regularly? You could be hurting your body’s ability
   to fight off Alzheimer’s disease. What you need to know
   July 14, 2023
   BY  Erin Prater

 * --------------------------------------------------------------------------------

 * Health
   Multimillionaire biohacker Bryan Johnson swipes back at Elon Musk’s criticism
   of his $2-million-a-year youth-chasing regimen: ‘He will fire you and leave
   you to die’
   January 03, 2024
   BY  Eleanor Pringle

 * --------------------------------------------------------------------------------

 * Health
   ‘Disease X’ could cause the next pandemic, according to the WHO—or Ebola,
   SARS, or Nipah. 9 pathogens researchers are keeping a watchful eye on
   January 12, 2024
   BY  Erin Prater

Rankings

 * 40 Under 40
 * 100 Best Companies
 * Fortune 500
 * Global 500

 * Most Powerful Women
 * World’s Greatest Leaders
 * World’s Most Admired Companies
 * See All Rankings

Sections

 * Finance
 * Leadership
 * Success
 * Tech

 * Asia
 * Europe
 * Environment
 * Fortune Crypto

 * Health
 * Well
 * Retail
 * Lifestyle
 * Politics

 * Newsletters
 * Magazine
 * Features
 * Commentary

 * MPW
 * CEO Initiative
 * Conferences
 * Personal Finance
 * Recommends
 * Coupons

Customer Support

 * Frequently Asked Questions
 * Customer Service Portal
 * Privacy Policy
 * Terms of Use
 * Single Issues for Purchase
 * International Print

Commercial Services

 * Fortune Brand Studio
 * Fortune Analytics
 * Fortune Conferences
 * Advertising
 * Business Development

About Us

 * About Us
 * Editorial Calendar
 * Work at Fortune
 * Behavioral Advertising Notice
 * Terms and Conditions
 * Site Map

 * Facebook
 * Twitter
 * Linked
 * Instagram
 * Pinterest

© 2022 Fortune Media IP Limited. All Rights Reserved. Use of this site
constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at
Collection and Privacy Notice | Do Not Sell/Share My Personal Information | Ad
Choices 
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and
other countries. FORTUNE may receive compensation for some links to products and
services on this website. Offers may be subject to change without notice.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its
licensors. All rights reserved. Terms & Conditions. Powered and implemented by
Interactive Data Managed Solutions.